Nanotechnology
Maturity
4 / 5
Basis, source, vintage
Mature as an enabling layer, and the clearest evidence is that its biggest deployment is not described in its own terms.
Source: Lipid nanoparticles: Onpattro (patisiran, Alnylam), the first FDA-approved LNP-RNA drug (2018); Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna) mRNA vaccines deployed at global scale on LNP delivery. Nanoscale dimensions are also the semiconductor norm (2018–2024)
What it is
Engineering at the scale of individual molecules and atoms, where material properties differ from their bulk behaviour.
What it does
It is an enabling layer rather than an application: coatings, filtration membranes, drug delivery, catalysts and semiconductor features all depend on it while rarely being described in its terms.
Common misconception
That it failed to deliver. It delivered continuously and invisibly, inside products described by their function rather than by their nanoscale engineering — which is what maturity usually looks like.
Steepens
- Critical Mineral and Resource Scarcity — moderate
- Energy Transition and Electrification — moderate
- Longevity and the Healthspan Gap — moderate
- Water Security — moderate
What would change its gradient
- Manufacturing scale-up for specific nanomaterials
- Toxicology and regulatory frameworks, which remain patchy
- Cost per unit area for membranes and coatings
Shares megatrends with
- Battery & Storage Chemistry
- Energy Price & Availability
- Fusion
- Hydrogen
- Materials Science
- Nuclear & SMR
In the book
Why the Future Arrives Unevenly — Ch. 9 — The Closing of the Planetary Envelope · Ch. 14 — How Hype Is Manufactured
Sources
- Mature as an enabling layer, and the clearest evidence is that its biggest deployment is not described in its own terms. Source: Lipid nanoparticles: Onpattro (patisiran, Alnylam), the first FDA-approved LNP-RNA drug (2018); Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna) mRNA vaccines deployed at global scale on LNP delivery. Nanoscale dimensions are also the semiconductor norm (2018–2024).